Category Archives: Neuroscience

Why our obsession with happy endings can lead to bad decisions – The Conversation UK

Alls well that ends well, wrote William Shakespeare over 400 years ago. The words may still seem to ring true today, but turns out they dont. We have just busted the old myth in a recent brain imaging experiment, published in the Journal of Neuroscience.

Experiences that end well are not necessarily good overall and experiences that end less well are not necessarily all that bad. For example, if you play five rounds of poker you get more overall enjoyment from winning twice in the middle than once at the end but we dont always realise this. In fact, one of the numerous foibles that prompt us to make poor decisions is an unwarranted preference for happy endings.

A happy ending means things got better as the experience unfolded. However focusing on happy endings can make us neglect what happened along the way. A happy ending may be brief and come after a long period of mediocrity.

Most of us enjoy it when our pleasant experiences are as long as possible, but at the same time we want things to end well. When Dumbledore died at the end of the Harry Potter film, some people might have felt that their whole experience was ruined. But enjoyment that has already been had should not be discounted because of a disappointing end. A long holiday with brilliant weather except for the last day is not worse overall than a much shorter holiday with good weather throughout.

However, this is exactly how some people feel about past experiences. And this obsession with things getting better and better all the time is a Bankers Fallacy focusing on short-term growth at the expense of long-term outcome. The core of the problem is a difference between what we enjoy while it lasts and what we want again after the final impression. Fixating on the happy end only maximises our final impression, not our overall enjoyment.

To examine this phenomenon, we invited 27 volunteers to take part in a virtual gambling experiment. The participants watched pots of money on a computer screen as gold coins of different sizes dropped into the pots one by one. A happy ending would be one where larger gold coins dropped at the end of the sequence.

The experiment took place in an MRI scanner, which allowed us to monitor the brains activity as the participants examined pairs of sequences of gold coins. After each pair they got to decide which pot they preferred.

It turned out that there is a good reason why people are attracted to happy endings. Computational analyses of the brain recordings showed that we register the value of an experience in two distinct brain regions. The overall value is encoded in a brain region called the amygdala, which has a mixed reputation. It has been argued that amygdala activation mediates emotional responses that can lead to irrational behaviour, but it has also been shown that it can rationally encode the outcome of economic saving strategies.

But the amygdalas influence on decision making is marked down by disincentive activity in a region called the anterior insula if a previous experience doesnt end well. The anterior insula is sometimes associated with processing negative experiences, such as disgust suggesting that some people are actively repulsed by the unhappy end.

In the gambling experiment, good decision makers picked the pots with the most money in total, regardless of whether they got larger gold coins at the end. They showed a strong representation of the overall value in the amygdala, whereas suboptimal decision makers had stronger activity in the anterior insula. In other words, good decision makers need to be able to overrule a displeasing impression of an experience, such as an unhappy end.

Lets say you are going out for dinner and you chose between a Greek and an Italian restaurant where youve been before essentially asking your brain to compute which meal was best last time. If all the dishes in the Greek restaurant were quite good then clearly the whole dinner was quite good. But if the Italian starter was so so, the main dish was only alright but the tiramisu at the end was amazing, then you might have formed an overly positive impression of that Italian restaurant because the meal had a happy ending.

Since these brain mechanisms operate whether we want it or not, they may be reinforced by human culture with its interest in manipulating our perceptions through advertising, propaganda, fake news and so forth exploiting our susceptibility to narrative and storytelling. No one is immune to advertising. The more institutions manipulate our thinking, the more our capacity to make good decisions is threatened.

Our intuitive brain really needs intervention from our more deliberate thinking processes to help us resist fake news and other manipulation. Most of us already know how to do this for example by writing a list of pros and cons to support ourselves into wiser decisions, rather than relying on our gut feeling.

So its not only Shakespeare who was wrong. If our daily behaviour becomes too narrowly focused on the immediate past, were missing out. We need to stop and think about what we are doing using our prefrontal cortex and overrule these impulses and focus on the most relevant aspect of the decision.

Visit link:
Why our obsession with happy endings can lead to bad decisions - The Conversation UK

Neuroscience Market Summary, Trends, Sizing Analysis and Forecast To 2025 – Express Journal

The latest Neuroscience market report covers all important aspects like growth driving factors, opportunities, and challenges that will govern the industry dynamics in the upcoming years. Besides, it offers an in-depth analysis of various industry segmentations to deliver a clear picture of the top revenue prospects in this business sphere.

According to seasoned experts, the market is expected to witness modest gains while registering a CAGR of XX% over the analysis period 2020-2025.

Speaking of the major developments in recent times, the global health crisis of Covid-19 has turned out to be a terrifying experience for most businesses except for healthcare industries. Although some have effectively modified their strategies or revisited the mission of the entire company to ensure success, others continue to face an influx of difficulties. Our meticulous research on this industry vertical aims to answer all your queries regarding the evolving environment and help you excel in the coming years.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/235869

Key points from the Neuroscience market report:

Neuroscience market segmentation:

Regional bifurcation: North America, Europe, Asia-Pacific, South America, Middle East & Africa, South East Asia

Product types: Whole Brain Imaging, Neuro-Microscopy, Electrophysiology Technologies, Neuro-Cellular Manipulation, Stereotaxic Surgeries, Animal Behavior and Other

Applications spectrum: Hospitals, Diagnostic Laboratories, Research Institutes and Other

Competitive outlook: GE Healthcare, Plexon, Mightex Bioscience, Siemens Healthineers, Tucker-Davis Technologies, Noldus Information Technology, NeuroNexus, Blackrock Microsystems, Thomas RECORDING GmbH, Phoenix Technology Group and Alpha Omega

Market segmentation

The Neuroscience market is split by Type and by Application. For the period 2021-2026, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

Key questions answered in the report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/235869

Read more from the original source:
Neuroscience Market Summary, Trends, Sizing Analysis and Forecast To 2025 - Express Journal

Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease – GlobeNewswire

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics(NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon in patients with Parkinsons disease. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. It has been rationally designed with the goal of balancing meaningful motor control activity while minimizing the side effects typical of drugs that non-selectively stimulate dopamine.

We are encouraged by the benefit-risk profile of tavapadon based on the efficacy results observed in Phase 2 trials, as well as the tolerability profile we have seen in our clinical program to date, said Raymond Sanchez, M.D., chief medical officer of Cerevel Therapeutics. We look forward to advancing the development of tavapadon and potentially bringing a differentiated, cornerstone therapy to Parkinsons patients at all stages of the disease as supported by a robust Phase 3 program.

The Phase 3 program includes three 27-week, double-blind, randomized, placebo-controlled, parallel-group trials designed to evaluate the efficacy, safety and tolerability of fixed doses (TEMPO-1) and flexible doses (TEMPO-2) of tavapadon as a monotherapy in patients with early-stage Parkinsons disease or as an adjunctive therapy to levodopa in patients with late-stage Parkinsons disease who are experiencing motor fluctuations (TEMPO-3).

Approximately 1,200 patients ages 40 to 80 years will be enrolled across all three trials. The primary endpoint of the TEMPO-1 and TEMPO-2 trials is the change from baseline in the Movement Disorder Society-Unified Parkinsons Disease Rating Scale (MDS-UPDRS) Part II and Part III combined score. The primary endpoint of the TEMPO-3 trial is the change from baseline in total daily on time without troublesome dyskinesia. A fourth 58-week, open-label, safety extension trial will also be conducted as part of the program.

As the companys most advanced therapeutic program, tavapadon has been evaluated in 272 subjects in Phase 1 and Phase 2 trials, including in both early- and late-stage Parkinsons patient populations, which is required for a broad indication in Parkinsons disease. Across Phase 1b and Phase 2 trials conducted to date, tavapadon has demonstrated motor control benefit with the potential for an improved tolerability profile relative to D2/D3-preferring agonists.

Initiation of the registration-directed Phase 3 program for tavapadon began in January 2020. In response to the COVID-19 pandemic, Cerevel Therapeutics paused screening and enrollment in all trials in March 2020 and has remained vigilant about participant safety and data integrity. Now that the program is resuming, the company expects preliminary data readouts in the first half of 2023.

About TavapadonTavapadon is a potent, orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors. This investigational therapeutic is being evaluated for the once-daily symptomatic treatment of Parkinsons disease.

About Parkinsons DiseaseApproximately 10 million people worldwide are living with Parkinsons disease, according to the Parkinsons Foundation. The disease is characterized by a progressive degeneration of dopaminergic neurons (the main source of dopamine) leading to a loss of critical motor and non-motor functions. Symptom severity and disease progression differ between individuals but typically include slowness of movement (bradykinesia), trembling in the extremities (tremors), stiffness (rigidity), cognitive or behavioral abnormalities, sleep disturbances and sensory dysfunction.1 There is no laboratory or blood test for Parkinsons disease, so a diagnosis is made based on clinical observation,2 which may contribute to an underestimation of the incidence of the disease.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinsons disease and substance use disorder. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

___________________

1 J Neurol Neurosurg Psychiatry. 2008;79:368-376. doi:10.1136/jnnp.2007.131045.2 Cold Spring Harb Perspect Med. 2012;2:a008870.

Follow this link:
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson's Disease - GlobeNewswire

Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester – Diverse: Issues in Higher Education

October 29, 2020 | :

Coming from an all-girls school in Jamaica to a public school in the United States, Dr. Monique Mendes had to adjust to her classes and American culture.

Despite all the changes, her interest in science never faded. She was always drawn to answering questions through the scientific process.

Mendes decided to pursue a biology degree at the University of Florida. However, while there, she found her passion for neuroscience while working in a lab.

Dr. Monique Mendes

[The lab] is where I had real hands on experiences working on a project from the beginning all the way to the end, says Mendes who earned a Ph.D. from the University of Rochester Medical Centers (URMC) Del Monte Institute for Neuroscience. I had to do all the experiments and I helped with writing the paper. That was where I realized that it was really exciting to be a part of science.

Her desire to pursue a Ph.D. came after she joined the McNair Scholars Program at the University of Florida. The program aims to support undergraduate students from underrepresented and low-income backgrounds. It offers mentorship, financial assistance and other resources to help students prepare for a doctoral degree.

As both a first-generation undergraduate and doctoral student, she relied on mentorship from faculty members.

I definitely had no idea what was going on in the beginning, she says. I was fortunate to have a number of mentors throughout my career that really put my success as a priority. Throughout the years, I gained the experience and the resources I needed to succeed.

At the end of July, Mendes defended her dissertation, The Kinetics of Microglial Ontogeny and Maturation in the Adult Brain.

[The focus] was really to understand how cells renew, how they mature and to do a real time analysis of their dynamic in the brain, she adds.

Upon graduating, Mendes was surprised to learn that she became the first Black woman in URMCs history to receive a Ph.D. in neuroscience.

I felt really incredibly empowered because I felt like I was setting the stage for more Black women to come to Rochester, she says, where they can feel like this is something they can do and something they can be successful at. Hopefully, I showed other women that this was possible.

Due to low representation of Black women within the field, Mendes felt that she never had another student or faculty member look like her in the classroom.

However, after initiatives such as the BlackInNeuro campaign launched on Twitter, she was able to meet more Black females in the field.

I think in the next couple of years, we are going to have a number of Black women in neuroscience, which is going to be fantastic, says Mendes.

To recruit more Black women into the neuroscience field, she recommends that schools or companies create more opportunities for them.

I would say create an environment that is not only diverse but inclusive and also paying attention to the cultures so that Black women can feel that this is a place for them, says Mendes. There is a seat at the table. I just think thats probably the most important thing.

Her accolades include being appointed as a fellow of the Neuroscience Scholars Program by the Society for Neuroscience and receiving the Edward Peck Curtis Award for Excellence in Teaching by a Graduate Student.

Additionally, Mendes became the first URMC graduate student to receive the F99/K00 NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience fellowship from the National Institute of Neurological Disorders in Stroke.

She recently began her post-doctoral fellowship at Stanford University in the lab of researcher Dr. Mark Schnitzer. There, she will focus on how glia cells impact memory and learning.

Mendes plans to transition to a faculty position at a research-intensive institution as well as become an advocate and mentor for students.

Outside of the science field, she plays violin and plans to join a community orchestra. Mendes musical interest stemmed from her time in Jamaica she began playing violin at the Immaculate Conception High School in Jamaica. Since then, she has played at weddings as well as for the Florida Youth Orchestra, the Brighton Symphony Orchestra and the Rochester Philharmonic Orchestra here in the United States.

It is a sense of community, says Mendes. It is nice to have something outside of science to relax. Surprisingly, orchestra is relaxing for me. People would think otherwise. But it feels good to have like a cohort of people that you can talk about something that you are all passionate about. I have had a lot of fun over the years.

This article originally appeared in the October 29, 2020 edition of Diverse. You can find it here.

Read more:
Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester - Diverse: Issues in Higher Education

Neuroscience Market Outlook and Opportunities in Grooming Regions 2027 – re:Jerusalem

CMI published a business research report on Neuroscience Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202026. Neuroscience Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

The global Neuroscience Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Neuroscience Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Get Free PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2487

Geographical segmentation of Neuroscience Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Neuroscience Market: Competitive Landscape

Leading players operating in the global Neuroscience Market include:Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Blackrock Microsystems LLC, Femtonics Ltd., Intan Technologies, LaVision Biotec GmbH, Mediso Medical Imaging Systems, Neuralynx Inc., NeuroNexus Technologies, Inc., Newport Corporation, Plexon Inc., Noldus Information Technology, Scientifica Ltd., Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

Scope of the Report

The key features of the Neuroscience Market report 2020-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Neuroscience Market. The structure of Neuroscience Market by identifying its various segments and sub-segments to help understanding the report.

Neuroscience Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Neuroscience Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Neuroscience Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Important Neuroscience Market Data Available In This Report:

Receive FREE Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2487

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)provides COVID-19 Vaccine Tracker for all the latest updates about COVID-19 Vaccine.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. ShahPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Continue reading here:
Neuroscience Market Outlook and Opportunities in Grooming Regions 2027 - re:Jerusalem

Seemingly Healthy College Student: I Didn’t Think It Could be a Stroke (But It Was) – Baptist Health South Florida

Canon McClure, 20, a junior at the University of Miami, woke up one day in August after an intense headache the previous day. Over the course of the new day, however, she realized something was very wrong. She felt some weakness on her right side and it became increasingly difficult for her to communicate with people.

Without any underlying health condition or any family medical history of concern, Ms. McClure was suffering the beginning of an ischemic stroke caused by a sizeable clot in her middle cerebral artery (MCA), as the stroke response team at Baptist Hospitals Miami Neuroscience Institute would soon diagnose.

(Watch now: Hear from stroke patient Cannon McClure as she shares her stroke recovery story, along with Italo Linfante, M.D., medical director of Neuroendovascular Surgery at Miami Neuroscience Institute and Miami Cardiac & Vascular Institute, and Kevin Abrams, M.D., chair division of Neuroradiology at Miami Neuroscience Institute. Video by Steve Pipho.)

She is majoring in vocal performance with a focus on classical music and opera.

I definitely knew that something was seriously wrong, but I didnt really consider that it might have been a stroke, recalls the UM student from Plano, Texas, who is majoring in vocal performance with a focus on classical music and opera. I just didnt think that strokes really happened to people my age and theres nothing in my family history of heart attack or stroke or blood clotting or anything.

This was Very Urgent

Initially,Ms. McClure was transported to nearby Doctors Hospital, part of Baptist HealthSouth Florida. But after an ER physician consulted with Kevin Abrams, M.D., chair division of Neuroradiology atMiami Neuroscience Institute, she was transported to BaptistHospital, where the Baptist Emergency Stroke Team (B.E.S.T.) took quick action.

This was, obviously, very urgent, said Dr. Abrams. She was in the early stages of an acute ischemic attack (the most common type of stroke). I saw that she was 20-years-old and didnt have that many severe symptoms, and the symptoms were from yesterday. I was concerned that she could fall through the cracks because she didnt look as bad as the CT scan showed.

Ms. McClureremembers a whole team of people waiting for her at BaptistHospital. Also anticipating her arrival was Italo Linfante, M.D., medical director ofNeuroendovascular Surgery at Miami Neuroscience Institute and Miami Cardiac & VascularInstitute.

Theystarted asking me questions: date of birth, emergency contacts, that kind ofthing, she said. And then we got to the outside the room where theywere going to do the procedure, and Dr. Linfante started talking to me abouthow they were going to get the clot out of my brain.

Dr. Linfantewas ready to perform a life-saving thrombectomy, a procedure during which acatheter is threaded into an artery and up through the neck until it reachesthe blood clot causing the stroke.

At that time, her brain was compensating very well for the lack of blood flow. Therefore, she did not have a severe neurological deficit. However, given the size of the blood clot and the location of the occlusion, if we would have not open the artery to restore normal blood flow, these patients worsen and can be left with severe disability or death, said Dr. Linfante. We were able to go up into the middle cerebral artery of the brain and able to remove the clot, which was actually very dense and well-constructed and therefore it would have not dissolved spontaneously without our intervention.

Cannon McClure with her parents.

Before the procedure, Dr. Linfante called up Ms. McClures parents, who live Texas. Dr. Linfante talked to my parents and the nurses talked to them. And they were able to make them feel a little bit reassured about what was going to happen to me, says Ms. McClure.

Back to Doing All of the Things I Did Before

Ms. McClurerecalls feeling better with her ability to communicate fully restored soonafter the procedure, which takes less than 30 minutes.

It wasbasically just a matter of the anesthesia completely wearing off and I was backto almost my normal self, she said. It took about a week or two,but eventually all the sensation came back to my right side. Now, Im able todo all of the things that I did before.

Dr. Abrams said Dr. Linfante sent him a screenshot of the large clot he extracted from her left middle cerebral artery. And he said that she was doing great and I couldnt have been happier, said Dr. Abrams. It really made my day. Shes 20 years old and I have two children that are about that age and are also in college. So, it really hit home for me.

Hole inthe Heart: Stroke Mystery Likely Solved

But how canan otherwise healthy 20-year-old suffer a stroke? After Ms. McClure underwentall her tests and screenings, that mystery was likely solved, explains Dr.Linfante. Ms. McClure was born with what is commonly known as a hole inthe heart. Medically speaking its a patent foramen ovale, or PFO,essentially a hole in the wall of tissue (septum) between the left and rightupper chambers of the heart.

At birth,the foramen ovale usually closes, and within a few months, it seals completelyin about 75 percent of births. When it remains open, it is called a PFO. Forthe vast majority of the millions of people with a PFO, it is not a problem,even though blood is leaking from the right atrium to the left. Problems canarise when that blood contains a clot, as in the case of what likely happenedto Ms. McClure, says Dr. Linfante.

Ms. McClure recently underwent a successful, minimally invasive procedure by interventional cardiologist Bernardo Lopez-Sanabria, M.D., at Miami Cardiac & Vascular Institute, to close the PFO.

I haveto take an aspirin every day (because of the stroke) just as a preventativemeasure, says Ms. McClure. They did say that closing the PFOgreatly reduces my risk of ever having a stroke again. So thats really reassuringbecause if you have a stroke, its more likely that youll have oneagain.

Tags: Miami Neuroscience Institute, stroke

See more here:
Seemingly Healthy College Student: I Didn't Think It Could be a Stroke (But It Was) - Baptist Health South Florida

PhD Student/Technician, Studying the Role of Neuroimmunity in Traumatic Brain injury job with UNIVERSITY OF HELSINKI | 231796 – Times Higher Education…

The Biology of Neuro-Immune interaction, HiLIFE-Neuroscience center at University of Helsinki, has an immediate opening for one PhD student/Technician position studying the role of neuroimmunity in Traumatic Brain Injury (TBI). This is an Academy of Finland, Research Council for Health, funded project.

We are a young, enthusiastic group (P.I. Francesco No, PhD, Academy of Finland fellow), seeking for excellence in neuroscience research. For group details, please see https://www.helsinki.fi/en/hilife-neuroscience-center/research/research-...

We are seeking an outstanding, highly motivated individual to join our team to conduct research activities in the field of neuroimmunity, using well-established and innovative techniques, such as flow cytometry and scRNAseq.

The successful candidate has previous research experience in flow cytometry and cell sorting, and knowledge of molecular techniques, including cloning, bulk RNA sequencing, and Western Blot. Previous experience in conducting/analyzing scRNAseq experiments will be regarded as a merit. The candidate will be expected to carry out experiments analyzing phenotype and transcriptome of T lymphocytes extracted from mouse tissues. The ideal candidate will also have research experience in confocal microscopy. The candidate is expected to be self-driven, to have strong work-capacity and enthusiasm for science, and to have good communication skills. The successful candidate will be involved in master students supervision, scientific reporting, and in further collaborations (national and international).

To be appointed as an early stage researcher, the candidate should be qualified to pursue postgraduate studies: i.e., s/he is required to have completed a suitable higher university degree or an equivalent education abroad, which would qualify the person for similar academic studies. The position of PhD Student imply that the Candidate successfully enrolls to one of the Doctoral Programmes at University of Helsinki.

The official language of the laboratory is English. A fluent English language proficiency is required.

The position is filled for a fixed term of one year, starting on 1.12.2020/as soon as possible or as agreed. The salary of the position is determined in accordance with the salary system of Finnish universities. Trial period of 6 months will be applied.

For further information on the position, please contact: Academy Fellow Francesco No, francesco.noe@helsinki.fi

Application should contain the following appendices:

The application needs to be submitted no later than 30.11.2020 (by 24.00 hours Finnish time).

Please submit your application via the University of Helsinki Recruitment System by clicking the Apply for the position button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment@helsinki.fi.

The University of Helsinki is an equal opportunity employer. International applicants are encouraged.

HiLIFE -Neuroscience Center

The Neuroscience Center is an international research unit within Helsinki Institute of Life Science (HiLIFE) of the University of Helsinki, a leading Nordic university with a strong commitment to life science research. The research focus of NC is on translational brain plasticity. We carry out research relevant for the human brain both in health and disease, and during development and aging, by applying versatile approaches and modern technology platforms. NC aims at making fundamental discoveries about brain functions and especially translate research findings into improvements in the treatment, prevention and diagnosis of psychiatric and neurological disorders. The research in NC spans across several scales from stem cell research and molecular neuroscience to systems and cognitive neuroscience in both animal and human models. The research groups of NC conduct research in neuroscience at the highest international level and actively apply the results for the benefit of the society. NC collaborates actively with other units of HiLIFE and faculties of the University of Helsinki, Helsinki University Central Hospital, and Neurocenter Finland.

Helsinki Institute of Life Science

Helsinki Institute of Life Science (HiLIFE) is a new institute established in 2017 that supports high quality life science research across the University campuses and faculties. HiLIFE builds on existing strengths and new recruits and partnerships to create an attractive international environment for researchers to solve grand challenges in health, food, and environment. HiLIFE coordinates research infrastructures in life sciences and provides research-based interdisciplinary training.

University of Helsinki

The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.

Due date

30.11.2020 23:59 EET

See the rest here:
PhD Student/Technician, Studying the Role of Neuroimmunity in Traumatic Brain injury job with UNIVERSITY OF HELSINKI | 231796 - Times Higher Education...

RNI researchers to study the impact of excessive speeds on the human brain, body – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Oct 30 2020

Before the first Virgin Hyperloop ride takes off, the brains behind pioneering neuroscience research at West Virginia University will help ensure the health and well-being of its passengers and operators.

After all, they'll be traveling in pods through a vacuum tube - at speeds breaking 600 mph.

It sounds like science fiction. But it will be a reality grounded in science, as engineers develop and tweak the mover system that will disrupt modern transportation as we know it.

Tried-and-tested science won't end there. Virgin Hyperloop plans to collaborate with the barrier-breaking Rockefeller Neuroscience Institute at WVU to study how traveling at excessive speeds may impact the brain and body.

The RNI, led by Dr. Ali Rezai, has heralded numerous breakthroughs in recent years, ranging from first-of-its-kind procedures treating Alzheimer's disease patients with focused ultrasound and those recovering from substance abuse through deep brain stimulation to predicting viral infections symptoms such as those associated with COVID-19 three days in advance through the use of wearable technology, a mobile app and artificial intelligence.

RNI researchers have already established the framework and tools that Virgin Hyperloop can apply at its certification center, which will span nearly 800 acres in Tucker and Grant counties.

Construction of the Hyperloop Certification Center will begin in 2021 with a planned Welcome Center, Certification Track and Operations Center, Pod Final Assembly Facility, Production Development Test Center and Operations, Maintenance and Safety Training Center.

That's where the tinkering until perfection takes place - before the system goes prime time. The plan is for Hyperloop to connect cities such as Pittsburgh and Chicago in 41 minutes, or New York City to Washington, D.C. in just 30 minutes.

Imagine zooming along at those 600 mph speeds in a tube with no windows. Or, better yet, operating the system itself.

These are super-high fast trains. Fundamentally, the RNI can collaborate with Virgin Hyperloop with a focus on safety, functionality and performance, for example, the neuroscience of workload, stress, cognitive ability and all other functions that can be quantified and measured, with respect to system users like passengers and operators."

Dr Ali Rezai, Executive Chair, Vice President, Neuroscience and Associate Dean of RNI, West Virginia University

"Human functions may be impacted by high speed and the perception of knowing how fast you are moving. Without windows and a frame of reference, a person's balance, sensor, motor and other nervous systems function may be impacted as well. We'll be looking at all of these factors in an integrated framework that measures physiological function and performance of the team and system operators and the passenger."

When the NBA restarted its 2019-20 season at Walt Disney World Resort over the summer, players had the option to wear a wedding band-like smart ring that could detect early COVID-19 symptoms.

Months earlier, at the onset of the coronavirus pandemic, the RNI teamed up with the ring maker, Oura Health, to develop a digital health platform to predict viral illness symptoms such as with COVID-19.

More than 600 healthcare professionals and first responders participated in the first phase of the RNI study. The rings worked.

They monitored physiological data including temperature, breathing and heart patterns, and when coupled with the RNI mobile app and its Digital Health platform, effectively predicted viral illness symptoms such as those associated with coronavirus for up to three days before appearing, with over 80 percent accuracy.

The RNI has all kinds of wearable gadgets, from wristwatches to even clothing, that constantly monitor a person's vitals and collect health data.

By applying artificial intelligence and machine-learning to the data collected, the RNI team has predicted health outcomes and behaviors, such as cravings of patients recovering from substance abuse. In fact, before the COVID-19 pandemic, a large chunk of wearable technologies deployed by the RNI were geared toward patients overcoming opioid addiction and chronic pain.

Now the RNI may help to test these smart technologies for the Virgin Hyperloop project.

"We are going to use wearable technologies to quantify the physiology of humans," Rezai said. "From eye trackers to body sensors to electrocardiograms and electroencephalograms, we can measure, quantify and make sense of what's happening to the human body at 600 mph."

"We will apply technologies that we have validated as state-of-the-art to measure physiological, cognitive, social, subjective and performance indicators," said Dr. Scott Galster, director of applied research at RNI.

Galster came to WVU in 2017 to head up human performance research at RNI after an extensive background with the Air Force Research Laboratory and working with NCAA and professional sports teams. He is the mind behind the muscle.

At the RNI, he and his team have continued work with military personnel and athletes, including WVU sports teams, to study fatigue, resilience and recovery.

Similarly, Virgin Hyperloop operators are like athletes and soldiers. They'll have a specific quest and must train to be fit, mentally and physically, to achieve that target.

"We want to optimize operator performance by creating competency-based training systems, applying our knowledge of interactions with complex automated systems examining factors such as decision-making, mental models and trust," Galster said.

RNI will also apply neuroergonomics - the study of the human brain in relation to behavioral performance in natural environments and settings - and cognitive engineering in the design and flow for the control center, Galster continued.

"We have, either internally or through our existing collaborator network, the ability to offer assistance in all aspects of the operational space for this exciting project," he said.

Galster, too, emphasized that Virgin Hyperloop will provide two unique experiences - one for the passenger and one for the operator.

For passengers, the RNI can examine and offer recommendations on the point-to-point experience that Virgin Hyperloop will offer, he said.

Examples include digital infrastructures to help from purchasing to arriving at your destination, environmental factors such as vibration, lighting, ergonomics, motion sickness, and the use of advanced recovery modalities during ride times.

The ultimate goal, Galster said, is to "make the entire system operate safely and securely with maximum efficiency and enjoyment now and in the future."

"The ecosystem we've established at West Virginia University Rockefeller Neuroscience Institute is already impacting individuals across different walks of life in improving not only their health and wellness, but job performance, recovery and readiness," Rezai said.

"At the Hyperloop Certification Center, we will be providing a scientific leadership role and guidance in characterizing and optimizing human safety and function related to this innovative hyperloop technology."

Read more here:
RNI researchers to study the impact of excessive speeds on the human brain, body - News-Medical.Net

Neuroscience The frog sees better when fleeing than when mating The animal’s vision depends on what vision is needed at any given time – Pledge Times

The ability of frogs to distinguish colors in the dark clearly surpassed even the fairly good vision of man.

Frog distinguishes colors better when fleeing than when mating, and the mouse perceives dim lights better at night than during the day. Thus, the sensitivity of vision depends on the behavioral task, according to a recent study by the University of Helsinki and Aalto University. dissertation research.

Petri Ala-Laurilan and Kristian Donnerin a research group led by led to find out what things limit the sensitivity of vision in low light and how close to the absolute limits set by physics visual performance can get.

Neuroscientist at the University of Helsinki Sanna Koskela says that vision is limited in low light, especially by two factors.

Light is divided into individual particles, or photons, and the stars in the night sky, for example, become only a few photons for the light-sensing cells of the eye. Light is quantized, that is, sometimes a flash of light becomes three photons and sometimes six. Such random variation sets the first physical limit on vision.

According to Koskela, however, this limit is almost impossible to achieve, as biological noise brings an additional challenge to night vision. It inevitably arises in all mechanisms of the nervous system, as there is some random variation associated with each molecule and biological process.

In studies it turned out that the vision of experimental frogs and mice in the dark reached surprisingly close to the absolute limits set by physics.

For example, the ability of frogs to distinguish colors in the dark clearly exceeded the quite good performance of the human visual sense under the right conditions.

However, performance depends on the context and the behavioral task, ie whether there has been an evolutionary need to push biological performance to the extremes, says Koskela.

The first study tested the color vision of frogs in near pitch black.

The frogs were selected as experimental animals because, unlike other vertebrates, they have two types of rod light sensory cells for night vision. At least two types of photosensitive cells are required for color vision, corresponding to different wavelengths of light, i.e. colors.

Color vision was tested in three different behavioral tasks: predation, pair selection, and escape. In the predation task, the frogs had to choose between two objects of different colors in the dimming lighting, and if chosen correctly, they were rewarded with a worm.

In the escape mission, the frog was enclosed in a light-tight container from which they tried to escape by jumping towards a light source on the roof. In previous experiments, it had been found that frogs prefer to jump towards the blue light because they interpret it as the sky.

The researchers compared the frogs jumps between two different colored light sources and found that in the escape mission, their night vision reached close to the extremes set by physics. This did not happen in other positions.

A frog in the rainforest of Borneo.Picture: SCUBAZOO / SCIENCE PHOTO LIBRARY

Similar observation was also made in mice. In the experiment, the mouse was swam into a pitch-dark labyrinth with dim light at the labyrinth exit. Mice were taught that light directed out of the maze, and slowly the light was dimmed. The experiment was repeated both night and day.

The researchers found a difference in behavior: mice found light better at night than during the day. The difference between the times of day was as much as tenfold.

To the researchers surprise, the difference was not explained by changes in the photosensitivity of the mices eyes but by the animals behavioral strategy. In nocturnal experiments, mice seek light more efficiently by turning more. The mice also observed the light source for a longer time before deciding where to go swimming in the maze.

When mice that participated in the night experiment did the same experiment during the day, they took advantage of this better strategy and cleared the maze more efficiently than mice that had not performed the experiment at night.

Never before have animal behavioral strategies been analyzed with such precision.

Koskelan according to one of the key challenges in neuroscience is to understand how neural calculations of neural networks determine animal behavior.

It is often almost impossible to study this, as there are billions of neural networks and calculations relevant to each behavioral state. It is therefore difficult to find out which neural networks are active at any given time and are responsible for a particular behavioral task.

For example, the retinal neural network makes an enormous number of calculations of light distribution to provide an idea of colors, shapes, and movements before this information is sent along the optic nerve to the brain.

Twilight vision simplifies these problems, because in pitch black, neural calculations mainly answer the simple question of whether you saw or did not see, says Koskela.

In the future, he would like to find out more about what causes different behavioral strategies in the brain according to task and time of day.

My own hypothesis is that these are areas of the brain that affect alertness and decision-making.

.

Follow this link:
Neuroscience The frog sees better when fleeing than when mating The animal's vision depends on what vision is needed at any given time - Pledge Times

Just too cute, season two – University of California

By J.D. Warren, UC RiversideThursday, October 29, 2020

With the second season of the hit Disney+ program The Mandalorian set to premier on Friday, October 30, the question of why Baby Yoda's fans want to squeeze him to the point of smothering him can be addressed at last.

Katherine Stavropoulos, a UC Riverside professor and expert on cute aggression, is a leader on research behind peoples' response to the Baby Yoda character. Cute aggression is the urge to squeeze, pinch, smother, or bite very cute things, including puppies, human babies, and Baby Yodas. Stavropoulos has used neuroscience to explore how this unique care-taking response is triggered, and how the aggression aspect is mediated by the brain.

Basically, Baby Yoda has all the features that we consider prototypically cute huge eyes, small nose, big head, Stavropoulos said. We are evolutionarily programmed to find things like Baby Yoda cute and to feel strong feelings towards them.

In a 2018 study, Stavropoulos used her backgrounds in neuroscience and clinical psychology to explore the neural component of cute aggression, a phenomenon first identified in a 2015 Yale University study. She found both the brain's reward and emotion systems were engaged by cute babies and animals. She also found that how cute something is and how much aggression one experiences can be tied to how overwhelmed that person is feeling.

For people who tend to experience the feeling of not being able to take how cute something is,cute aggression happens. Our study seems to underscore that cute aggression is the brain's way of bringing us back downby mediating our feelings of being overwhelmed, Stavropoulos said. It's a sort of evolutionary process, designed for example to help a mother stop being overwhelmed by her baby's cuteness so she's not incapacitated, and can take care of the baby.

Here is a link to a story about Stavropoulos' research. To reach Stavropoulos, email her atkatherine.stavropoulos@ucr.edu.

Excerpt from:
Just too cute, season two - University of California